CDP-choline accumulation in breast and colorectal cancer cells treated with a GSK-3-targeting inhibitor.

Su Myat PhyuChih-Chung TsengTim Andrew Davies Smith

Published in: Magma (New York, N.Y.) (2018)

SB216763 profoundly inhibits phospholipid synthesis in cancer cells which demonstrate accumulation of CDP-choline detectable by 31P NMR spectroscopy. Metabolic changes in lipid metabolism present potential response markers to drugs targeting GSK3.

Keyphrases

signaling pathway
cancer therapy
pi k akt
fatty acid
drug delivery
climate change